EmstoPA is a first in class antibody-based reversal agent to treat bleeding caused by tissue plasminogen activator (tPA - Activase®, Alteplase®). tPA is a “clot buster” used to remove the blood clots that cause stroke, pulmonary embolism, and myocardial infarction. In the developed world, tPA is most frequently used to treat acute ischemic stroke where the rates of subsequent intracranial hemorrhage (ICH) are 5-7% .
EmstoPA belongs to a class of drugs called anti-fibrinolytics, and and the current market for antifibrinolytics is estimated to be $1,100m /year. Currently no specific tPA reversal agents are in
development.
Company Details
- Founded
- -
- Address
- Discovery Park, Ramsgate Road, Sandwich,ct13 9ff,united Kingdom
- Phone
- +44 01304 892398
- ad****@****opa.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- emstopa.com
- Keywords
- Sandwich.
- HQ
- Sandwich
Emstopa Questions
Emstopa's helpline number is +44 01304 892398
Emstopa's website is emstopa.com
Emstopa's LinkedIn profile is https://uk.linkedin.com/company/emstopa
Emstopa's industry is
Pharmaceutical Manufacturing
Emstopa's top competitors are
Psyros Diagnostics,
Stem At Kent,
Granular Therapeutics Ltd,
Slm Waste Management Ltd,
Quvium Uk,
Inhalytic Limited,
Farmitalia Carlo Erba Limited,
Tetrad Discovery Ltd (Cro),
Vox Imaging Technology Ltd,
Wavedx.
Emstopa's support email address is admin@emstopa.com
Emstopa's categories are Pharmaceutical Manufacturing
Emstopa's founding year is 2017
